Submitted by: Submitted by vasu123
Views: 10
Words: 729
Pages: 3
Category: Business and Industry
Date Submitted: 05/04/2016 11:24 PM
Viibryd (Major Depressive Disorder) Market Size, Share, Trends, Company
Profiles, Demand, Insights, Analysis, Research, Report, Opportunities,
Segmentation and Forecast To 2023
Summary
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide.
The MDD market is a crowded and competitive market, with more than 30 marketed products
available for the treatment of patients with MDD. The depression market is about to enter a
dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's
Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal
antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of
seven promising late-stage pipeline products into the market during the forecast period, from
2013 to 2023.
Viibryd (vilazodone) is an SSRI and a 5HT1A receptor partial agonist indicated for the treatment
of patients with MDD. Viibryd was licensed from Merck KGaA and developed by Forest
(Actavis). Currently, it is only available in the US market and, in 2013, generated sales of
$162.5m (Forest Laboratories, 2014).
To Get More Details @ http://www.radiantinsights.com/research/viibryd-majordepressive-disorder-forecast-and-market-analysis-to-2023
Scope
- Overview of Major depressive disorder, including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview on the competitive
landscape.
- Detailed information on Viibryd including product description, safety and efficacy profiles as
well as a SWOT analysis.
- Sales forecast for Viibryd for the US from 2013 to 2023.
- Sales information covered for the US.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major
depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the...